Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Beta-blocker vs. Ic Antiarrhythmic Drug for PVC
NCT03561935 · Yong Seog Oh · NA · withdrawn · last registry update 2024-04-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Yong Seog Oh |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRB1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-20Phase 3 first posted: Jagiellonian University, noradrenaline infusion for management blood pressure + standard blood pressure management (NCT06885268)
- 2025-03-03Phase 3 first posted: Ain Shams University, ACE Inhibitors + β -Blockers (NCT06853951)
- 2025-01-29Results posted on the registry: Beaver-Visitec International, Inc., a drug against ADRB1 (NCT04176965)
- 2024-11-29Results posted on the registry: University of Pennsylvania, a drug against ADRB1 (NCT03646643)
- 2024-11-20Phase 3 first posted: Shanghai Changzheng Hospital, Carvedilol and alverine (NCT06696248)
- 2024-11-19Results posted on the registry: OnPoint Vision Inc, a drug against ADRB1 (NCT04984590)
- 2024-10-30Results posted on the registry: Alcon Research, a drug against ADRB1 (NCT05481125)
- 2024-07-24Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Βeta-Blockers discontinued (with tapering) (NCT06518694)
- 2024-06-24Phase 3 first posted: Shanghai Changzheng Hospital, Alverine + Carvedilol (NCT06470386)
- 2024-06-03Also stopped (terminated): Asociación para Evitar la Ceguera en México, a drug against ADRB1 (NCT00925886)
- 2024-05-30Also stopped (terminated): Asociación para Evitar la Ceguera en México, a drug against ADRB1 (NCT00802269)
- 2024-05-28Results posted on the registry: Bausch & Lomb Incorporated, a drug against ADRB1 (NCT04192630)
- 2024-05-01Phase 3 first posted: Universitas Indonesia, Dexmedetomidine + Fentanyl (NCT06394375)
- 2024-04-16Results posted on the registry: University at Buffalo, Carvedilol Controlled Release (CR) + lisinopril (NCT00430040)
- 2024-04-16Also stopped (terminated): University at Buffalo, Carvedilol Controlled Release (CR) + lisinopril (NCT00430040)
- 2024-04-09Results posted on the registry: Weill Medical College of Cornell University, Beta blockers (NCT04757584)
- 2024-02-16Phase 3 first posted: University Hospital, Tours, Experimental group: Patients will be treated with carvedilol. (NCT06263816)
- 2023-12-26Results posted on the registry: University of New Mexico, carvedilol + metoprolol (NCT00642434)
- 2023-12-08Also stopped (terminated): University of Toronto, a drug against ADRB1 (NCT03409185)
- 2023-10-25Phase 3 first posted: Humanitas Clinical and Research Center, Cannabidiol and β-Caryophyllene Patch (NCT06099171)
- 2023-10-23Results posted on the registry: AbbVie, ABBV-951 (NCT03781167)
- 2023-09-29Results posted on the registry: Children's Oncology Group, Carvedilol (NCT02717507)
- 2023-08-21Results posted on the registry: Alcon Research, a drug against ADRB1 (NCT03316885)
- 2023-07-14Phase 3 first posted: Milton S. Hershey Medical Center, Oxymetazoline 0.1% (Pf) Oph Soln Ud (NCT05945615)
- 2023-07-05Phase 3 first posted: VA Office of Research and Development, Metoprolol Succinate + Carvedilol (NCT05931276)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision